Replimune Group マネジメント

マネジメント基準チェック /24

Replimune Groupの CEO はSush Patelで、 Apr2024年に任命され、の在任期間は 1 年未満です。は、会社の株式の0.074%を直接所有しており、その価値は$ 751.70K 。経営陣と取締役会の平均在任期間はそれぞれ1.2年と6.4年です。

主要情報

Sush Patel

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.07%
経営陣の平均在職期間	1.2yrs
取締役会の平均在任期間	6.4yrs

経営陣の近況

Recent updates

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16

Replimune: In The 'Buy Zone' Again

Oct 01

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Sep 02

Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business

May 24

Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic

Apr 30

We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow

Feb 08

Replimune Group EPS misses by $0.03

Feb 04

Dosing underway in Replimune's early-stage cancer study with gene therapy

Jan 05

CEO報酬分析

Replimune Group の収益と比較して、Sush Patel の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$213m
Jun 30 2024	n/a	n/a	-US$220m
Mar 31 2024	n/a	n/a	-US$216m
Dec 31 2023	n/a	n/a	-US$210m
Sep 30 2023	n/a	n/a	-US$199m
Jun 30 2023	n/a	n/a	-US$182m
Mar 31 2023	US$3m	US$447k	-US$174m
Dec 31 2022	n/a	n/a	-US$157m
Sep 30 2022	n/a	n/a	-US$147m
Jun 30 2022	n/a	n/a	-US$133m
Mar 31 2022	US$7m	US$394k	-US$118m

報酬と市場: Sushの総報酬がUS市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Sushの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Sush Patel (53 yo)

less than a year

在職期間

US$2,595,003

報酬

Dr. Sushil Patel, also known as Sush,Ph D, is CEO & Director of Replimune Group, Inc. from April 1, 2024. Dr. Patel served as the Chief Commercial Officer at Replimune Group, Inc. since May 3, 2021 and ser...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Philip Astley-Sparke	Executive Chairman	9.8yrs	US$6.02m	1.86% $ 19.0m
Emily Hill	Chief Financial Officer	1.2yrs	US$3.61m	0.017% $ 177.5k
Konstantinos Xynos	Chief Medical Officer	1.9yrs	US$2.45m	0.017% $ 169.4k
Sushil Patel	CEO & Director	less than a year	US$2.60m	0.074% $ 751.7k
Robert Coffin	Founder	no data	US$5.72m	2.57% $ 26.2m
Andrew Schwendenman	Chief Accounting Officer & Treasurer	1.5yrs	データなし	0.010% $ 104.8k
Christopher Sarchi	Chief Commercial Officer	1.9yrs	データなし	0.017% $ 177.7k
Paul Bullock	Chief Manufacturing Officer & Framingham Site Head	less than a year	データなし	データなし

1.2yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: REPLの経営陣は経験豊富とはみなされません ( 1.2年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Philip Astley-Sparke	Executive Chairman	9.8yrs	US$6.02m	1.86% $ 19.0m
Sushil Patel	CEO & Director	less than a year	US$2.60m	0.074% $ 751.7k
Robert Coffin	Founder	9.8yrs	US$5.72m	2.57% $ 26.2m
Joseph Slattery	Independent Director	7.1yrs	US$362.60k	0.0097% $ 99.5k
Hyam Levitsky	Independent Non-Executive Director	6.5yrs	US$355.10k	0% $ 0
Paolo Pucci	Independent Director	4.6yrs	US$360.10k	0% $ 0
Madhavan Balachandran	Director	less than a year	データなし	データなし
Kapil Dhingra	Independent Director	7.3yrs	US$357.60k	0% $ 0
Christy Oliger	Independent Director	2.9yrs	US$352.60k	0% $ 0
Dieter Weinand	Lead Independent Director	6.4yrs	US$516.81k	0% $ 0
Veleka Peeples-Dyer	Independent Director	1.4yrs	US$667.97k	0% $ 0

6.4yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: REPLの取締役会は経験豊富であると考えられます ( 6.4年の平均在任期間)。

Replimune Group マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Chief Financial Officer recently sold US$91k worth of stock

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Chief Medical Officer notifies of intention to sell stock

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024

Chief Medical Officer recently sold US$80k worth of stock

Recent updates

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

New minor risk - Share price stability

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune: Strong Data In A Highly Differentiated Space

Chief Financial Officer recently sold US$91k worth of stock

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Consensus revenue estimates decrease by 50%, EPS upgraded

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Price target increased by 8.2% to US$14.67

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Chief Medical Officer notifies of intention to sell stock

Price target increased by 9.2% to US$14.56

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

New minor risk - Share price stability

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Replimune: Continuing To Justify The Bear Thesis (For Now)

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Now 25% undervalued after recent price drop

Price target decreased by 64% to US$17.22

New minor risk - Share price stability

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Chief Medical Officer recently sold US$80k worth of stock

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

New major risk - Revenue and earnings growth

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Chief Business Officer exercised options and sold US$250k worth of stock

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Chief Business Officer notifies of intention to sell stock

Chief Strategy Officer notifies of intention to sell stock

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates fall by 42%

CEO & Director recently sold US$323k worth of stock

No longer forecast to breakeven

Insufficient new directors

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune Group, Inc. Announces Executive Appointments

Chief Business Officer exercised options and sold US$360k worth of stock

Price target increased to US$48.89

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune secures $200M term loan

Replimune: Recent Developments Strengthen Bull Thesis

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune Group GAAP EPS of -$0.78 misses by $0.15

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold US$156k worth of stock

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Chief Operating Officer notifies of intention to sell stock

Replimune: In The 'Buy Zone' Again

マネジメント基準チェック /24